Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin

Revista de Investigacion Clinica

Volumn 55, Issue 2, 2003, Pages 138-142

  Gallegos Orozco, Juan Fernando ^a   Fuentes, Ana Paula ^a   Olivera Martinez, Marco Antonio ^a   Gutiérrez Reyes, Gabriela ^a   Cortina, Diego ^a   Oregel, Jesús Alberto ^a   Pérez Pruna, Christian ^a   Sixtos, María Sara ^a   Cruz Castellanos, Socorro ^a   Soto Ramírez, Luis Enrique ^a   Rodríguez Díaz, Roberto ^a   Fuentes Romero, Luis ^a   Gutiérrez Ruiz, María Concepción ^b   Kershenobich, David ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b DEPARTAMENTO DE QUÍMICA   (Mexico)

Author keywords

Chronic hepatitis C.; Early viral response; Hepatitis C virus; Peginterferon alfa 2b; Ribavirin; Serum HCV RNA

Indexed keywords

ALPHA INTERFERON; IMMUNOMODULATING AGENT; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGE; AGED; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INDICATION; DRUG RESPONSE; FEMALE; FOOD INTAKE; GENDER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PHASE 3 CLINICAL TRIAL; PREDICTION; RNA ANALYSIS; TIME; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD; VIREMIA;

EID: 0038724240     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. EASL International Consensus Conference on Hepatitis C. Consensus statement. J Hepatol 1999; 30: 956-61.
2. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chro-nic hepatitis C. N Engl J Med 1998; 339: 1485-92.
3. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.
4. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon α-2a in non-cirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-8.
5. Zeuzem S, Feinman SV, Rasenack JJ, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
6. Heathcote EJ, Shiffman ML, Cooksley WGE, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-80.
7. Manns MP, McHutchison JG, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational, phase III randomized controlled trial. Hepatology 2000; 32(pt. 2): 297A.
8. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282: 103-7.
9. Herrmann E, Neumann AU, Schmidt JM, Zeuzem S. Hepatitis C virus kinetics. Antivir Ther 2000; 5: 85-90.
10. Zeuzem S. Clinical implications of hepatitis C viral kinetics. J Hepatol 1999; 31 (Suppl. 1): 61-4.
11. Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M, Esteban R. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002; 35: 930-6.
12. Zeuzem S, Lee J-H, Franke A, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27: 1149-56.
13. Zeuzem S, Schmidt JM, Lee J-H, et al. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28: 245-52.
14. Zeuzem S, Schmidt JM, Lee J-H, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23: 366-71.
15. McHutchison JG, Shad JA, Gordon SC, Morgan TR, Ling MH, Garaud JJ, Albrecht JK, Dienstag JL. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J Viral Hep 2001; 8: 414-20.
16. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, Layden TJ. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28-35.